Shenyang Pharmaceutical University Licenses Nanodrug 'GPS' Technology for Tumor-Targeted Delivery to Guangzhou Zhigao Point Pharma

Jun 05, 2026 08:00 CST Updated 08:00

In cancer treatment, a more challenging problem than “failing to kill cancer cells” is“How to Kill Only Cancer Cells”。

The surface of tumor cells is covered with a sialic acid (SA)-rich “glycocalyx.”, this sugar coating is not only a “cloak of invisibility” for cancer cells, helping them evade immune surveillance, but also a passport for their metastasis and dissemination. Clinically, existing drug delivery systems lack precise targeting capabilities; drugs often act indiscriminately after administration, resulting in limited efficacy and significant side effects.

An intuitive idea is:Since tumors have an affinity for sialic acid, drug carriers can be modified with sialic acid to guide drugs specifically to the tumor site.—This is the rationale behind ligand-targeted modification. However, existing sialic acid modification technologies have long been confronted with a triple dilemma:

• Cumbersome Synthesis Steps

• Low grafting ratio

• Poor reaction efficiency

It’s like trying to craft a precision key when your tools only allow you to grind with a hammer. Low yield and poor stability make it difficult to truly translate into clinical products.

Shenyang Pharmaceutical University recently100,000 yuanPutA Patent for a Sialic Acid Lipid DerivativeTransferred to Guangzhou Zhigaodian Pharmaceutical Technology Co., Ltd., this challenge has been thoroughly restructured from the perspective of chemical synthesis.

Core Innovation: Redesigning the Forging Process of Keys

Under conventional approaches, when sialic acid is grafted onto the surface of liposomes,Steric Hindranceis the greatest obstacle. The key cannot fit into the lock. The R&D team introduced flexible spacer groups,Adopting the "Amidation–Electroshock Reaction–Amidation" Three-Step Process, rendering originally intractable reactions mild, controllable, and efficient.

The core value of this step lies not merely in creating a “key,” but in inventing a reusable, standardized process—enabling sialic acid modification to be applied across diverse carriers (liposomes, nanoparticles, micelles, etc.) using a unified logic, thereby making large-scale mass production feasible.

Dual Mechanism: From Broad-Spectrum Screening to Precision Targeting

At the molecular level, this technology achieves precise delivery through two pathways:

Active Targeting.Leveraging the natural affinity of sialic acid for specific receptors in the tumor microenvironment to enable active drug targeting.Passive stealth. The modified derivatives mimic signals on the surface of human cells, exhibiting excellent hemocompatibility, reducing nonspecific clearance by the reticuloendothelial system, and prolonging the drug’s half-life.

The superposition of two mechanisms enables precise targeting.Versatility represents an even greater value proposition: this derivative can seamlessly integrate with liposomes, emulsions, solid lipid nanoparticles, micelles, and even mRNA delivery systems. This means that Guangzhou High Ground’s existing pipeline of generic anti-tumor drugs, mRNA vaccines, or novel anti-inflammatory agents can directly achieve enhanced targeting simply by incorporating this modification module.

Why is Guangzhou the High Ground?

Professor Deng Yihui, Shenyang Pharmaceutical UniversityWith a long-term focus on research into drug delivery systems, they have accumulated extensive expertise in areas such as PEGylated carriers and long-circulating liposomes. The sialic acid lipid derivatives designed by their team have undergone systematic validation from molecular structure to synthesis process, demonstrating clear potential for drug development.

For Guangzhou's strategic high ground, the actual value of this RMB 100,000 transaction lies in:Exchange a single compound patent for the capability to targetedly upgrade multiple pipelines.The company has deeply cultivated medical research and biochemical engineering technologies. By introducing this platform-level technology, it can rapidly build differentiated barriers based on its existing products—a highly cost-effective leveraged transaction with clear clinical value and a well-defined translation logic.The platform demonstrates considerable scalability,This is the core highlight of the RMB 100,000 patent transfer.